PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer

PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer

Regorafenib, targeting a broad range of receptor tyrosine kinases (RTKs), is an oral multikinase inhibitor which improves the progression-free survival (PFS) and overall survival (OS) of patients diagnosed with chemorefractory metastatic colorectal cancer (mCRC), making an immunosuppressive tumour m...

Full description

Bibliographic Details
Main Authors: Lucrezia Raimondi, Filippo Maria Raimondi, Laura Di Benedetto, Giuseppe Cimino, Gian Paolo Spinelli
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:International Journal of Molecular Sciences
Subjects:
chemorefractory metastatic colorectal cancer
regorafenib
circulating tumour cells
PD-L1
PLR
liquid biopsy
Online Access:https://www.mdpi.com/1422-0067/21/18/6907

Internet

https://www.mdpi.com/1422-0067/21/18/6907

Similar Items